Hibercell
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
619 W 54th St Fl 8, New York City, New Y...Phone Number
(651) 675-0300Website
www.hibercell.comRevenue
$11.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Hibercell
HiberCell is focused on developing innovative therapies that target adaptive-stress driven vulnerabilities in cancer cells to combat treatment resistance, cancer relapse, and metastasis. Their clinical-stage therapeutic candidates, including HC-7366, HC-5404, and Odetiglucan, aim to exploit stress-induced vulnerabilities to enhance patient outcomes. The company is led by a team of experienced biotech executives committed to combining traditional drug development with computational expertise. HiberCell's mission is to improve the lives of cancer patients by pioneering new treatment paradigms.Explore more
Hibercell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hibercell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Hibercell launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Hibercell is spiking on competitors!
Funding: Get notified immidiatlly once Hibercell has new funding data
Earning: See what the market has to say on Hibercell recently announced quarterly report
Website visits: Recent activity has been detected on your website
Hibercell, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Hibercell had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Hibercell
Check if Hibercell has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Hibercell as Masked Content
Find 3 more new buyers
Compare Similar Companies to Hibercell
Compare insights from companies similar to Hibercell, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
<$5M
1997
JA
Joseph AttawayChief Financial Officer & Shareholder & Partner & Co-Founder
Company Profile Activity
Activity Insights
Hibercell is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hibercell is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hibercell.
Hibercell financials insights
Gather financial insights about Hibercell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$60.8M
2021
Debt
$30M
Series B
$67.4M
Hibercell Tech Stack
A closer look at the technologies used by Hibercell
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Left Company
Executive Move
Project
A mid-level source in Financial Planning has indicated that the organization has completed initiatives related to board reporting within the last nine months.
Financial Planning, Board of Directors
Project
A mid-level source in Financial Planning has indicated that the organization has completed initiatives related to budget creation and management within the last nine months.
Financial Planning
Project
Financial Planning, Forecasting
Hibercell News & Media
HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)
ROSEVILLE, Minn., April 14, 2026 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the preclinical poster presentation titled, Combination of the GCN2 activator HC-7366 with VEGFR-TKI results in greater efficacy than VEGFR-TKI alone or VEGFR-TKI/HIF-2i combinations in ccRCC which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2026, taAVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound
– First-in-Human PERK inhibitor (HC-5404) to be developed in combination with AVEO's FOTIVDA® (tivozanib) for RCC – – AVEO obtains option to an exclusive license for the development, manufacturing, and commercialization of HC-5404 – BOSTON, Nov. 4, 2025 /PRNewswire/ -- AVEO Oncology, an...HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the successful completion of the dose escalation portion of its Phase 1b study evaluating HC-7366—an activator of the integrated stress response (ISR) kinase GCN2—in combination with Merck’s (known as MSD outside the US and Canada) oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, WELIREG® (belzutifHiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Hibercell
Sign Up For FreeTo access detailed company insights
HiberCell is focused on developing innovative therapies that target adaptive-stress driven vulnerabilities in cancer cells to combat treatment resistance, cancer relapse, and metastasis. Their clinical-stage therapeutic candidates, including HC-7366, HC-5404, and Odetiglucan, aim to exploit stress-induced vulnerabilities to enhance patient outcomes... Read More
